本月热点
Arcellx’s BCMA CAR-T challenges Legend’s Carvykti in multiple myeloma;
Eli Lilly's Imlunestrant, an oral SERD, significantly improved PFS in ER+, HER2- advanced breast cancer patients;
Merck/VelosBio’s ROR1-directed ADC on top of R-CHP showed 100% ORR in 1L DLBCL, with safety signals to inform Phase 3 study of the low dose;
BMS’ TYK2 inhibitor Sotyktu succeeds in two phase 3 trials of psoriatic arthritis;
Merus’ petosemtamab showed standard-of-care potential in 2L+ HNSCC while its zenocutuzumab received FDA accelerated approval to treat NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma;
Janux Therapeutics’ JANX007 showed promising interim phase 1a data in patients with advanced prostate cancer;
Novo Nordisk’s CagriSema showed 22.7% weight loss in a phase 3 obesity trial, falling short of high expectations；
AbbVie announced positive topline results for the third phase 3 trial of Tavapadon in Parkinson’s Disease；
Novartis pays $1B upfront for PTC518, a phase 2 oral drug for Huntington’s Disease;
BMS pays $100M upfront to collaborate with BioArctic on Alzheimer’s drugs.
活动详情
活动直播伙伴
共建Biomedical创新生态圈！
如何加入BiG会员？
